Docetaxel (Trihydrate)

• UNSPSC Description:

  Docetaxel Trihydrate (RP-56976 Trihydrate) is an antineoplastic agent and inhibits microtubule depolymerization with an IC50 value of 0.2 μM[1]. Docetaxel Trihydrate is a semisynthetic analog of taxol and attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel Trihydrate arrests the cell cycle at G2/M and leads to cell apoptosis[1][3].

• Target Antigen:

  Apoptosis; Microtubule/Tubulin

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage;Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/docetaxel-trihydrate.html

• Purity:

  99.92

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)|Ethanol : 50 mg/mL (ultrasonic)

• Smiles:

  O=C(OC(C)(C)C)N[C@H]([C@H](C(O[C@@H]1C(C)=C([C@@H](O)C([C@@]2(C)[C@]([C@@](CO3)(OC(C)=O)[C@@]3([H])C[C@@H]2O)([H])[C@@H]4OC(C5=CC=CC=C5)=O)=O)C(C)(C)[C@@]4(O)C1)=O)O)C6=CC=CC=C6.O.O.O

• Molecular Weight:

  861.93

• References & Citations:

  [1]Attia RT, et al. The chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells. PeerJ. 2016 Jun 29;4:e2168.|[2]Che CL, et al. DNA microarray reveals different pathways responding to paclitaxel and docetaxel in non-small cell lung cancer cell line. Int J Clin Exp Pathol. 2013 Jul 15;6(8):1538-48.|[3]Obi-Ioka Y, et al. Involvement of Wee1 in the circadian rhythm dependent intestinal damage induced by docetaxel. J Pharmacol Exp Ther. 2013 Oct;347(1):242-8.|[4]Li C, et al. Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. J Pharm Biomed Anal. 2016 Sep 5;128:286-93.Br J Pharmacol. 2024 Jul 9.|Cell Rep Methods. 2023 Oct 23;3(10):100599.|ACS Appl Mater Interfaces. 2023 Apr 21.|ACS Appl Mater Interfaces. 2024 Aug 6.|ACS Nano. 2021 Apr 27;15(4):7179-7194.|ACS Omega. 2024 Feb 28;9(10):11870-11882.|ACS Sens. 2023 Jan 27.|Acta Pharm Sin B. 2020 June 29.|Adv Funct Mater. 2023 Dec 15.|Anticancer Drugs. 2022 Oct 1;33(9):871-882.|Arch Biochem Biophys. 2023 Feb 21;109551.|Biochem Biophys Rep. 2024 Mar, 37, 101639.|Biochem Pharmacol. 2020 May;175:113865.|Biofabrication. 2023 May 26.|Biol Direct. 2024 Sep 11;19(1):79.|Biomark Res. 2022 Jul 13;10(1):48.|Biomaterials. 2 September 2022, 121783.|Biomed Chromatogr. 2022 May 28.|Biomed Pharmacother. 2023 Apr 25;163:114751.|Biomed Pharmacother. 2023 Jun 15;165:115023.|bioRxiv. 2023 Nov 1.|Breast Cancer Res Treat. 2023 May 19.|Breast Cancer Res. 2024 Mar 19;26(1):48.|Cancer Cell Int. 2024 Jul 17;24(1):249.|Cancer Immunol Res. 2023 May 3;11(5):583-599.|Cancer Lett. 2023 Aug 5;216338.|Cancer Sci. 2023 Dec 20.|Cancers. 2020 Jul 28;12(8):2092.|Cell Biosci. 2023 Nov 25;13(1):215.|Cell Death Dis. 2024 Aug 7;15(8):571.|Cell Mol Gastroenterol Hepatol. 2021;11(3):683-696.|Cell Rep Med. 2023 Jan 10;100911.|Cell Rep. 2024 Jul 3;43(7):114431.|Chem Biol Interact. 2023 Mar 1;373:110372.|Clin Transl Oncol. 2022 Jul 19.|Diabetes. 2022 Oct 18;db220231.|Discov Oncol. 2023 May 27;14(1):82.|Drug Deliv Transl Res. 2021 Oct;11(5):2030-2051.|Eur J Histochem. 2022 Oct 25;66(4).|Eur J Med Chem. 2018 Feb 25;146:157-170.|Eur Urol. 2020 Nov 2;S0302-2838(20)30778-8.|FEBS J. 2024 May 7.|Front Oncol. 2019 Dec 19;9:1398.|Genome Med. 2024 Jan 12;16(1):11.|Int J Cancer. 2024 Jul 15;155(2):324-338.|Int J Clin Exp Pathol. 2017;10(3):3033-3042.|Int J Mol Med. 2024 Jul;54(1):60.|Int J Mol Sci. 2019 Jan; 20(1): 28.|Int J Mol Sci. 2022 Nov 19;23(22):14385.|Int J Pharm. 2023 Mar 13;122846.|J Agric Food Chem. 2024 Jul 17.|J Appl Polym Sci. 18 February 2022.|J Biol Chem. 2021 Jan 8;100276.|J Cancer Res Clin Oncol. 2022 Aug 12.|J Cell Mol Med. 2022 Feb 27.|J Colloid Interface Sci. 2022 May 2;622:789-803.|J Control Release. 2021 Jan 10;329:847-857.|J Control Release. 2022 Dec 9;353:490-506.|J Control Release. 2024 Nov 5:376:829-841.|J Exp Clin Cancer Res. 2023 Aug 18;42(1):209.|J Hematol Oncol. 2023 May 3;16(1):46.|J Immunother Cancer. 2021 Jul;9(7):e001758.|J Liposome Res. 2020 Jun;30(2):182-196. |J Microencapsul. 2019 Sep;36(6):552-565.|J Microencapsul. 2020 Dec;37(8):543-556.|J Oncol. 10 Mar 2022.|Life Sci. 2020 Sep 1;256:117983.|Life Sci. 2021 Jan 1;264:118674.|Mat Sci Eng C-Mater. 2021, 111956.|Materials. 2020 Mar 2;13(5):1099.|Mol Biol Res Commun. 2022 Mar;11(1):11-20.|Mol Cancer. 2024 May 9;23(1):83.|Mol Med Rep. 2020 Jul;22(1):67-76.|Nanotheranostics. 2021 Jan 1;5(2):143-154.|Nanotheranostics. 2021; 5(2): 143-154.|Oncol Lett. 2022 Mar;23(3):101.|Oncotarget. 2016 May 17;7(20):28891-902.|Oncotarget. 2017 Dec 2;8(68):112313-112329.|Oxid Med Cell Longev. 24 May 2022.|Patent. US20230145200A1.|Pharm Dev Technol. 2021 Jul 19;1-33.|Pharmaceuticals. 2024 Apr 29, 17(5), 569.|Pharmacol Res. 2024 May 9:204:107208.|Phytomedicine. 14 January 2022, 153939.|Phytomedicine. 2022: 154584.|Phytomedicine. 2023 Jun 8, 154921.|Phytomedicine. 2024 Oct 18:135:156155.|Preprints. 2023 Jul 13.|Proc Natl Acad Sci U S A. 2023 Apr 25;120(17):e2218522120.|Research Square Preprint. 2021 Jan.|Research Square Print. November 29th, 2022.|Sci Rep. 2023 Jun 3;13(1):9043.|Sci Rep. 2024 Mar 27;14(1):7303.|Sci Transl Med. 2024 Apr 3;16(741):eadj5705.|Seoul National University. Molecular medicine and Biopharmaceutical sciences. 2021 Dec.|Signal Transduct Target Ther. 2022 Sep 12;7(1):317.|SSRN. 2024 Mar 22.|Transl Lung Cancer Res. 2024 Oct 31;13(10):2698-2712.|Transl Oncol. 2023 Jun 24;35:101723.|University of Adelaide. 2023 Jan.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  148408-66-6